Literature DB >> 30713785

Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells.

Fiamma Salerno1, Aurelie Guislain1, Julian J Freen-Van Heeren1, Benoit P Nicolet1, Howard A Young2, Monika C Wolkers1.   

Abstract

Protective T cell responses against tumors require the production of Interferon gamma (IFN-γ). However, tumor-infiltrating T cells (TILs) gradually lose their capacity to produce IFN-γ and therefore fail to clear malignant cells. Dissecting the underlying mechanisms that block cytokine production is thus key for improving T cell products. Here we show that although TILs express substantial levels of Ifng mRNA, post-transcriptional mechanisms impede the production of IFN-γ protein due to loss of mRNA stability. CD28 triggering, but not PD1 blocking antibodies, effectively restores the stability of Ifng mRNA. Intriguingly, TILs devoid of AU-rich elements within the 3'untranslated region maintain stabilized Ifng mRNA and produce more IFN-γ protein than wild-type TILs. This sustained IFN-γ production translates into effective suppression of tumor outgrowth, which is almost exclusively mediated by direct effects on the tumor cells. We therefore conclude that post-transcriptional mechanisms could be modulated to potentiate effective T cell therapies in cancer.

Entities:  

Keywords:  B16 melanoma; CD28; IFN-γ; PD-1; Tumor-infiltrating T cells; mRNA stability; post-transcriptional regulation

Year:  2018        PMID: 30713785      PMCID: PMC6343783          DOI: 10.1080/2162402X.2018.1532762

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  50 in total

1.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

2.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta.

Authors:  Kelly-Ann Sheppard; Lori J Fitz; Julie M Lee; Christina Benander; Judith A George; Joe Wooters; Yongchang Qiu; Jason M Jussif; Laura L Carter; Clive R Wood; Divya Chaudhary
Journal:  FEBS Lett       Date:  2004-09-10       Impact factor: 4.124

3.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.

Authors:  Yoshiko Iwai; Seigo Terawaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2004-12-20       Impact factor: 4.823

4.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

5.  Apoptotic cell thrombospondin-1 and heparin-binding domain lead to dendritic-cell phagocytic and tolerizing states.

Authors:  Alon Krispin; Yaniv Bledi; Mizhir Atallah; Uriel Trahtemberg; Inna Verbovetski; Efrat Nahari; Orly Zelig; Michal Linial; Dror Mevorach
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Authors:  Victor Appay; Camilla Jandus; Verena Voelter; Severine Reynard; Sarah E Coupland; Donata Rimoldi; Danielle Lienard; Philippe Guillaume; Arthur M Krieg; Jean-Charles Cerottini; Pedro Romero; Serge Leyvraz; Nathalie Rufer; Daniel E Speiser
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

7.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Authors:  Alfred Zippelius; Pascal Batard; Verena Rubio-Godoy; Gilles Bioley; Danielle Liénard; Ferdy Lejeune; Donata Rimoldi; Philippe Guillaume; Norbert Meidenbauer; Andreas Mackensen; Nathalie Rufer; Norbert Lubenow; Daniel Speiser; Jean-Charles Cerottini; Pedro Romero; Mikaël J Pittet
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

8.  Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.

Authors:  Helena Harlin; Todd V Kuna; Amy C Peterson; Yuru Meng; Thomas F Gajewski
Journal:  Cancer Immunol Immunother       Date:  2006-02-09       Impact factor: 6.968

9.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Authors:  Yoshiko Iwai; Masayoshi Ishida; Yoshimasa Tanaka; Taku Okazaki; Tasuku Honjo; Nagahiro Minato
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

10.  Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation.

Authors:  M Stein; S Keshav; N Harris; S Gordon
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

View more
  14 in total

Review 1.  CD8+ T cell states in human cancer: insights from single-cell analysis.

Authors:  Anne M van der Leun; Daniela S Thommen; Ton N Schumacher
Journal:  Nat Rev Cancer       Date:  2020-02-05       Impact factor: 60.716

Review 2.  Sequence determinants as key regulators in gene expression of T cells.

Authors:  Benoit P Nicolet; Nordin D Zandhuis; V Maria Lattanzio; Monika C Wolkers
Journal:  Immunol Rev       Date:  2021-09-05       Impact factor: 10.983

3.  The relationship of mRNA with protein expression in CD8+ T cells associates with gene class and gene characteristics.

Authors:  Benoît P Nicolet; Monika C Wolkers
Journal:  PLoS One       Date:  2022-10-19       Impact factor: 3.752

Review 4.  CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.

Authors:  Sasan Ghaffari; Nastaran Khalili; Nima Rezaei
Journal:  J Exp Clin Cancer Res       Date:  2021-08-26

Review 5.  Post-transcriptional control of T-cell cytokine production: Implications for cancer therapy.

Authors:  Julian J Freen-van Heeren
Journal:  Immunology       Date:  2021-05-10       Impact factor: 7.215

Review 6.  Using CRISPR to enhance T cell effector function for therapeutic applications.

Authors:  Julian J Freen-van Heeren
Journal:  Cytokine X       Date:  2020-12-21

Review 7.  CD8+ T cell differentiation and dysfunction in cancer.

Authors:  Mary Philip; Andrea Schietinger
Journal:  Nat Rev Immunol       Date:  2021-07-12       Impact factor: 108.555

8.  Human T cells employ conserved AU-rich elements to fine-tune IFN-γ production.

Authors:  Julian J Freen-van Heeren; Branka Popović; Aurélie Guislain; Monika C Wolkers
Journal:  Eur J Immunol       Date:  2020-03-18       Impact factor: 5.532

9.  Naïve CD8 T cell IFNγ responses to a vacuolar antigen are regulated by an inflammasome-independent NLRP3 pathway and Toxoplasma gondii ROP5.

Authors:  Angel K Kongsomboonvech; Felipe Rodriguez; Anh L Diep; Brandon M Justice; Brayan E Castallanos; Ana Camejo; Debanjan Mukhopadhyay; Gregory A Taylor; Masahiro Yamamoto; Jeroen P J Saeij; Michael L Reese; Kirk D C Jensen
Journal:  PLoS Pathog       Date:  2020-08-27       Impact factor: 6.823

Review 10.  Type I and II Interferons in the Anti-Tumor Immune Response.

Authors:  Sarah E Fenton; Diana Saleiro; Leonidas C Platanias
Journal:  Cancers (Basel)       Date:  2021-03-02       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.